Brief: Candel Therapeutics Research And Development Day Presentations Spotlight Its Advanced Pipeline And Capabilities To Develop Novel Viral Immunotherapies For Patients With Cancer

Candel Therapeutics

06/12/2022 21:40

Dec 6 (Reuters) - Candel Therapeutics Inc  CADL.O :
    * CANDEL THERAPEUTICS RESEARCH AND DEVELOPMENT DAY
PRESENTATIONS
SPOTLIGHT ITS ADVANCED PIPELINE AND CAPABILITIES TO DEVELOP
NOVEL VIRAL IMMUNOTHERAPIES FOR PATIENTS WITH CANCER
    * CANDEL THERAPEUTICS INC - PORTFOLIO DECISION MADE TO
PRIORITIZE
CAN-3110 IN HGG AND NOT TO PURSUE PHASE 3 CLINICAL TRIAL OF
CAN-2409 IN HGG
    * CANDEL THERAPEUTICS - PORTFOLIO DECISION MADE TO
PRIORITIZE
CAN-3110 IN HGG, NOT TO PURSUE PHASE 3 CLINICAL TRIAL OF
CAN-2409 IN HGG
    * CANDEL THERAPEUTICS INC - REAFFIRMED GUIDANCE OF PHASE 2
AND 3
CLINICAL TRIALS OF CAN-2409 IN PROSTATE CANCER
    * CANDEL THERAPEUTICS - PHASE 3 CLINICAL TRIAL IN LOCALIZED
INTERMEDIATE/HIGH-RISK PROSTATE CANCER EXPECTED TO READ OUT IN
Q4 2024 (EVENT-DRIVEN ENDPOINT)
    * CANDEL THERAPEUTICS- PHASE 2 CLINICAL TRIAL IN ACTIVE
SURVEILLANCE, LOCALIZED PROSTATE CANCER EXPECTED TO READ OUT IN
Q4 2023 (EVENT-DRIVEN ENDPOINT)

Source text for Eikon:  ID:nGNX1tNS14 
Further company coverage:  CADL.O 
 ((Reuters.Briefs@thomsonreuters.com;;))